On August 9, 2022, Asieris Pharmaceuticals, a global biopharmaceutical company
specializing in the discovery and development of innovative drugs for the
treatment of genitourinary tumors and other major diseases, announced that the
multinational Phase III Clinical Trial of APL-1702 (Cevira[®]), a novel non
-surgical treatment of cervical high-grade squamous intraepithelial lesions
(HSIL), has successfully enrolled 402 patients in the study two months ahead of
schedule. Additionally, Photocure received a $1 million milestone payment from
Asieris related to the ongoing clinical development of Cevira.
APRICITY is a multicenter, prospective, double-blind, randomized controlled
Phase III study further evaluating the efficacy and safety of the integrated
drug-and light-delivery device Cevira[®] in the treatment of HSIL. The clinical
trial was approved by the National Medical Products Administration (NMPA) in
July 2020 and was conducted simultaneously at 65 sites in 8 countries including
China, Germany, Hungary and the Netherlands. The first patient was dosed in
November 2020.
Cervical cancer is the fourth most common cancer in women worldwide[1]. In 2020,
604,000 new cases and 342,000 deaths worldwide were attributed to cervical
cancer.[1,2 ]Current treatments of HSIL of the cervix are based on invasive
surgical interventions, compromising cervical competence and functionality.
Currently, no non-surgical approach is available for the treatment of
precancerous cervical lesions.
Read Asieris' full press release here: https://asieris.com/asieris-multinational
-phase-iii-clinical-trial-for-the-non-surgical-treatment-of-hsil-has-completed
-enrollment/
1. Cervical cancer. Available from: https://www.who.int/health-topics/cervical
-cancer
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49
Note to editors:
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA
About Cevira[®]:
Cevira is a breakthrough photodynamic drug-device combination product that is
being developed for non-surgical treatment of high-grade precancerous lesions of
the cervix. Cevira holds the potential to serve the high unmet medical need for
non-invasive treatment options for patients with HSIL in an outpatient setting,
especially for young women of reproductive age. Asieris Pharmaceuticals entered
into a license agreement with Photocure ASA (Photocure, PHO: OSE) to obtain the
worldwide development and commercialization of Cevira in July 2019. Cevira[®] is
a registered trademark of Photocure ASA, based in Oslo, Norway.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no